Advocacy intelligence hub — real-time data for patient organizations
⚡ Live Alerts
Otsuka Pharmaceutical Development & Commercialization, Inc. — PHASE3
Sohag University — PHASE1
Egoo Health Aps — NA
Mansoura University — PHASE4
NGGT INC. — PHASE1
University of Missouri-Columbia — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Foundation Grants6
Good Days — Phenylketonuria
Good Days
Patient Services Inc — Phenylketonuria
Patient Services Inc
PAN Foundation — Phenylketonuria
PAN Foundation
NORD Patient Assistance — Phenylketonuria
NORD Patient Assistance
HealthWell Foundation — Phenylketonuria
HealthWell Foundation
The Assistance Fund — Phenylketonuria
The Assistance Fund
Copay Assistance3
Sephience
(SEPIAPTERIN)Orphan drugPTC Therapeutics Inc.
Palynziq
(PEGVALIASE-PQPZ)Orphan drugBioMarin Pharmaceutical Inc.
Sapropterin Dihydrochloride
(SAPROPTERIN DIHYDROCHLORIDE)Orphan drugAurobindo Pharma Limited
Kuvan
(sapropterin)Orphan drugstandardBioMarin Pharmaceutical, Inc.
12.1 Mechanism of Action KUVAN is a synthetic form of BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through a...
Neil Smith, PharmD
Censa Pharmaceuticals
Debra Lounsbury
BioMarin Pharmaceutical
Martina Huemer, Prof
University Childrens Hospital Zürich
📍 Zurich
Gary Hubbard, Dr
Nutricia UK Ltd
📍 Birmingham
Rajavel Elango, PhD
BC Children's Hospital Research Institute, University of British Columbia
📍 Vancouver, British Columbia
Anita MacDonald
Birmingham Women's and Children's NHS Foundation Trust
📍 Birmingham